Scholarly Smackdown: The Stem Cell Debate
Two ethical scholars plunge into the scientific and moral divide over embryonic stem cell research.
Ronald M. Green, chair of the department of religion at Dartmouth College, serves on the Ethics Advisory Board of Advanced Cell Technology, a biotechnology company.
Nigel Cameron is research professor of bioethics at Chicago-Kent College of Law and president of the Institute on Biotechnology and the Human Future.
Anyone who concluded from Ron Reagan's remarks that stem cells promise an imminent cure for Alzheimer's disease is mistaken. Stem cell transplant therapies for neurological diseases are still years away, and then most probably for conditions like Parkinson's disease. The damage caused by the buildup of diseased cells and plaques in Alzheimer's disease is so extensive that it is hard to see how any transplant could help.
Nevertheless, Ron Reagan is right for several reasons to stress the importance of stem cell research and to appeal for a change in current regulations.
First, a journey of many miles requires a first step. Research begun now with adequate federal support will undoubtedly lead to breakthroughs, some of them currently unanticipated. I fail to understand the logic of those who oppose research because the benefits are not presently obvious. Research is always a step into the unknown. You would not do research if you knew the answers.
Second, even though it is unlikely that stem cells will soon lead to therapeutic transplants, these technologies (including the use of biomedical cloning) can help us produce a series of model cell lines exhibiting the Alzheimer pathology. This will allow us to study the disease progression in the laboratory and better understand what goes wrong with neuronal functioning where the disease is present.